344 related articles for article (PubMed ID: 25188323)
21. Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis.
Lococo F; Torricelli F; Lang-Lazdunski L; Veronesi G; Rena O; Paci M; Casadio C; Piana S; Novellis P; Di Stefano TS; Ciarrocchi A; Billè A
J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1584-1593.e2. PubMed ID: 31590954
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey.
Ceresoli GL; Grosso F; Zucali PA; Mencoboni M; Pasello G; Ripa C; Degiovanni D; Simonelli M; Bruzzone A; Dipietrantonj C; Piccolini E; Beretta GD; Favaretto AG; Giordano L; Santoro A; Botta M
Br J Cancer; 2014 Jul; 111(2):220-6. PubMed ID: 24918816
[TBL] [Abstract][Full Text] [Related]
23. Post-recurrence chemotherapy for mesothelioma patients undergoing extrapleural pneumonectomy.
Takuwa T; Hashimoto M; Matsumoto S; Kondo N; Kuribayash K; Nakano T; Hasegawa S
Int J Clin Oncol; 2017 Oct; 22(5):857-864. PubMed ID: 28439676
[TBL] [Abstract][Full Text] [Related]
24. Relationship between prognosis and neutrophil: lymphocyte and platelet:lymphocyte ratios in patients with malignant pleural mesotheliomas.
Cihan YB; Ozturk A; Mutlu H
Asian Pac J Cancer Prev; 2014; 15(5):2061-7. PubMed ID: 24716935
[TBL] [Abstract][Full Text] [Related]
25. Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes.
Linton A; Soeberg M; Broome R; Kao S; van Zandwijk N
Respirology; 2017 Jul; 22(5):978-985. PubMed ID: 28139858
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study.
Wu TH; Lee LJ; Yuan CT; Chen TW; Yang JC
J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):230-236. PubMed ID: 29709339
[TBL] [Abstract][Full Text] [Related]
27. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma.
Gomez DR; Hong DS; Allen PK; Welsh JS; Mehran RJ; Tsao AS; Liao Z; Bilton SD; Komaki R; Rice DC
J Thorac Oncol; 2013 Feb; 8(2):238-45. PubMed ID: 23247629
[TBL] [Abstract][Full Text] [Related]
28. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
Kircheva DY; Husain AN; Watson S; Kindler HL; Durkin A; Vigneswaran WT
Eur J Cardiothorac Surg; 2016 Jun; 49(6):1642-7. PubMed ID: 26802143
[TBL] [Abstract][Full Text] [Related]
29. Trimodality Treatment of Malignant Pleural Mesothelioma: An Institutional Review.
Kapeles M; Gensheimer MF; Mart DA; Sottero TL; Kusano AS; Truong A; Farjah F; Laramore GE; Stelzer KJ; Patel SA
Am J Clin Oncol; 2018 Jan; 41(1):30-35. PubMed ID: 26353120
[TBL] [Abstract][Full Text] [Related]
30. Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.
Billé A; Krug LM; Woo KM; Rusch VW; Zauderer MG
J Thorac Oncol; 2016 Feb; 11(2):249-55. PubMed ID: 26845118
[TBL] [Abstract][Full Text] [Related]
31. Impact of induction therapy on postoperative outcome after extrapleural pneumonectomy for malignant pleural mesothelioma: does induction-accelerated hemithoracic radiation increase the surgical risk?
Mordant P; McRae K; Cho J; Keshavjee S; Waddell TK; Feld R; de Perrot M
Eur J Cardiothorac Surg; 2016 Sep; 50(3):433-8. PubMed ID: 27005976
[TBL] [Abstract][Full Text] [Related]
32. Is Pleurectomy/Decortication Superior to Extrapleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma? A Single-Institutional Experience.
Miyazaki T; Yamasaki N; Tsuchiya T; Matsumoto K; Kamohara R; Hatachi G; Nagayasu T
Ann Thorac Cardiovasc Surg; 2018 Apr; 24(2):81-88. PubMed ID: 29367501
[TBL] [Abstract][Full Text] [Related]
33. Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma.
Baldini EH; Richards WG; Gill RR; Goodman BM; Winfrey OK; Eisen HM; Mak RH; Chen AB; Kozono DE; Bueno R; Sugarbaker DJ
J Thorac Cardiovasc Surg; 2015 May; 149(5):1374-81. PubMed ID: 25772281
[TBL] [Abstract][Full Text] [Related]
34. Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy's and St Thomas' hospitals.
Bille A; Belcher E; Raubenheimer H; Landau D; Cane P; Spicer J; Lang-Lazdunski L
Gen Thorac Cardiovasc Surg; 2012 May; 60(5):289-96. PubMed ID: 22453539
[TBL] [Abstract][Full Text] [Related]
35. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis.
Magge D; Zenati MS; Austin F; Mavanur A; Sathaiah M; Ramalingam L; Jones H; Zureikat AH; Holtzman M; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2014 Apr; 21(4):1159-65. PubMed ID: 24322529
[TBL] [Abstract][Full Text] [Related]
36. Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.
Sugarbaker DJ; Wolf AS; Chirieac LR; Godleski JJ; Tilleman TR; Jaklitsch MT; Bueno R; Richards WG
Eur J Cardiothorac Surg; 2011 Aug; 40(2):298-303. PubMed ID: 21310625
[TBL] [Abstract][Full Text] [Related]
37. The new case for cervical mediastinoscopy in selection for radical surgery for malignant pleural mesothelioma.
Nakas A; Waller D; Lau K; Richards C; Muller S
Eur J Cardiothorac Surg; 2012 Jul; 42(1):72-6; discussion 76. PubMed ID: 22290929
[TBL] [Abstract][Full Text] [Related]
38. The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
Giroux Leprieur E; Hirata T; Mo M; Chen Z; Okamoto J; Clement G; Li H; Wislez M; Jablons DM; He B
Lung Cancer; 2014 Sep; 85(3):465-71. PubMed ID: 25023662
[TBL] [Abstract][Full Text] [Related]
39. Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma.
Vigneswaran WT; Kircheva DY; Ananthanarayanan V; Watson S; Arif Q; Celauro AD; Kindler HL; Husain AN
Ann Thorac Surg; 2017 Mar; 103(3):962-966. PubMed ID: 27765170
[TBL] [Abstract][Full Text] [Related]
40. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
